Brahim_av schreef op 28 juni 2024 10:57:
Om terug te komen op Mithra's verkochte Assets...
In het persbericht van G.R. (Budapest, 11 June 2024 –)
The transaction includes the acquisition of 100% of the shares in Estetra SRL (“Estetra”) and
Neuralis SA (“Neuralis”), as well as some assets and licences of Mithra R&D.
The enterprise value implied by the transaction is EUR 175mn, including assumed net debt.
Mithra’s key asset is its own-developed lead platform, based on Estetrol (E4), a unique, native
estrogen. The transaction aims to acquire exclusive rights of this molecule for multiple
indications and several synthetic approaches thereof, as well as worldwide rights attached to
the linked product/product candidates. The transfer includes the related intellectual property
rights, current contracts as well as the commitments related to ESTELLE® (already marketed)
and DONESTA® (in development, ahead of filing for marketing authorization).
Voorlopig is er enkel een voorschot betaald van de €175M.
Weet iemand of G.R. met zijn nieuwe rechten op Estetrol, Donesta zelf gaat verkopen in de VS
of een partner gaat zoeken?
Voor Estelle neem ik aan de ze verder gaan met Mayne Pharma aan we ze nu leveren...